Lv1
60 积分 2022-09-26 加入
Compound EGFR mutations are predominantly PACC (P-loop and alpha-C helix compressing) mutations with increased responsiveness to second- vs third-generation tyrosine kinase inhibitors
3个月前
已关闭
P3.12.38 Updated Clinical Results From FURTHER: A Study of Firmonertinib in TKI-Naive, Advanced NSCLC With EGFR PACC Mutations
3个月前
已关闭
EGFR V834L and L858R Comutation Is Associated With Response to Osimertinib in Non-Small-Cell Lung Cancer
5个月前
已完结
Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
8个月前
已完结
NK cells with tissue-resident traits shape response to immunotherapy by inducing adaptive antitumor immunity
9个月前
已完结
DNA methyltransferase 3A (DNMT3A) mutations and PD-(L)1 blockade efficacy in non-small cell lung cancer
1年前
已关闭
皖公网安备34019202002308
